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Background. The Met allele of the catechol-O-methyltransferase (COMT) valine-to-methionine (Val158Met) poly-
morphism is known to aﬀect dopamine-dependent aﬀective regulation within amygdala–prefrontal cortical (PFC)
networks. It is also thought to increase the risk of a number of disorders characterized by aﬀective morbidity
including bipolar disorder (BD), major depressive disorder (MDD) and anxiety disorders. The disease risk conferred
is small, suggesting that this polymorphism represents a modiﬁer locus. Therefore our aim was to investigate how
the COMT Val158Met may contribute to phenotypic variation in clinical diagnosis using sad facial aﬀect processing as
a probe for its neural action.
Method. We employed functional magnetic resonance imaging to measure activation in the amygdala, ventromedial
PFC (vmPFC) and ventrolateral PFC (vlPFC) during sad facial aﬀect processing in family members with BD (n=40),
MDD and anxiety disorders (n=22) or no psychiatric diagnosis (n=25) and 50 healthy controls.
Results. Irrespective of clinical phenotype, the Val158 allele was associated with greater amygdala activation and the
Met158 allele with greater signal change in the vmPFC and vlPFC. Signal changes in the amygdala and vmPFC were
not associated with disease expression. However, in the right vlPFC the Met158 allele was associated with greater
activation in all family members with aﬀective morbidity compared with relatives without a psychiatric diagnosis
and healthy controls.
Conclusions. Our results suggest that the COMT Val158Met polymorphism has a pleiotropic eﬀect within the neural
networks subserving emotional processing. Furthermore the Met158 allele further reduces cortical eﬃciency in the
vlPFC in individuals with aﬀective morbidity.
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Introduction
Catechol-O-methyltransferase (COMT) provides the
main mechanism for the degradation of released cor-
tical dopamine (DA) (Karoum et al. 1994 ; Gogos et al.
1998). Its gene contains a common functional poly-
morphism at codon 158/108 which results in the sub-
stitution of valine (Val) for methionine (Met) in the
COMT peptide sequence (Lotta et al. 1995 ; Lachman
et al. 1996). As the Val158 isoform is more active than
the Met158 in degrading DA (Lotta et al. 1995 ; Lachman
et al. 1996 ; Mannisto & Kaakkola, 1999) this poly-
morphism has important ramiﬁcations for functions
involving DA neurotransmission, such as cognition
and aﬀect regulation.
Carriers of the Val158 allele show impaired per-
formance (Egan et al. 2001 ; Joober et al. 2002 ; Bosia
et al. 2007) coupled with increased dorsal prefrontal
cortical (PFC) activation during executive function
tasks (Mattay et al. 2003 ; Blasi et al. 2005 ; Bertolino
et al. 2006a, b ; Schott et al. 2006 ; Winterer et al. 2006 ;
Mier et al. 2009). In contrast the Met158 allele is associ-
ated with greater reactivity to emotionally negative
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stimuli as evidenced by increased activation in the
ventral PFC and associated limbic regions (Smolka
et al. 2005 ; Drabant et al. 2006 ; Mier et al. 2009). Based
on these observations it is thought that optimal func-
tion of the dorsal and ventral PFC is respectively
associated with the Met158 and Val158 alleles ; this con-
fers an advantage in executive function for Met car-
riers and in emotional resilience for Val carriers (Mier
et al. 2009).
Because of its eﬀect on cognitive and emotional
function the COMT gene has been considered in many
psychiatric disorders. Key associations have been
noted between the Val158 allele and schizophrenia
(Glatt et al. 2003) and between the Met158 allele and
disorders of aﬀective morbidity such as anxiety dis-
orders (Hamilton et al. 2002 ; Woo et al. 2002), bipolar
disorder (BD) (Craddock et al. 2006) and possibly
major depressive disorder (MDD) (Ohara et al. 1998 ;
Massat et al. 2005). As the disease risk conferred is
very small and not consistently detected, the COMT
Val158Met may primarily act as a modiﬁer locus,
having an impact on disease-associated traits such
as brain function or cognition, rather than clinical
diagnosis.
Here we used functional magnetic resonance
imaging (fMRI) to examine the relationship between
the COMT Val158Met polymorphism and clinical diag-
nosis in families from the Vulnerability to Bipolar
Disorders Study (VIBES; Frangou, 2009) where more
than one member had an aﬀective disorder. Detecting
the eﬀect of modiﬁer genes is diﬃcult in human
studies because environmental factors cannot be stan-
dardized and because participants diﬀer in many
genes in addition to the gene of interest. By restricting
the study to individuals that share a genetic pre-
disposition to BD we might be able to reduce genetic
variability relevant to the inﬂuence of the COMT
polymorphism on brain processes. Apart from
patients with BD, a signiﬁcant proportion of relatives
from the VIBES sample have MDD or anxiety dis-
orders. This allowed us to investigate whether the role
of the COMT genotype on neural networks relating
to aﬀective processing is consistent across a number
of clinical diagnoses characterized by aﬀective dis-
turbance. Additionally, the sample includes psychi-
atrically healthy relatives and unrelated healthy
controls that could inform on clinically silent eﬀects
of the genotype on neural circuitry.
We chose a sad aﬀect categorization task as a probe
for two reasons. First, emerging evidence suggests
a relative speciﬁcity for abnormal sad facial aﬀect
processing in mood disorders (Keedwell et al. 2009).
Second, the task engages a widespread neural
network believed to underlie emotional processing
(Adolphs, 2002 ; Phan et al. 2002 ; Murphy et al. 2003).
This network involves a number of anatomically and
functionally interconnected regions primarily encom-
passing the cingulate cortex and the dorsal and ventral
PFC, the amygdala and insula (Amaral & Price, 1984 ;
LeDoux, 2000 ; Dolan, 2007 ; Fairhall & Ishai, 2007). In
this study we were particularly interested in the
amygdala and in the ventromedial and ventrolateral
PFC based on three lines of inquiry : (a) previously
published data of abnormal engagement of these re-
gions during facial aﬀect processing in patients with
aﬀective morbidity (Domschke et al. 2008 ; Foland et al.
2008 ; Lee et al. 2008) ; (b) evidence that activity within
these regions during negative emotional processing is
modulated by the COMT Val158Met polymorphism
(Kempton et al. 2009; Mier et al. 2009) ; and (c) the ex-
plicit processing of facial aﬀect during categorization
tasks consistently engages ventral, and particularly
ventrolateral, PFC regions which are thought to rep-
resent the neural basis of modulatory control of
emotional experiences (Hariri et al. 2000 ; Foland et al.
2008). Additionally, our regions of interest (ROI)
within the amygdala and the PFC overlap with those
implicated in current models for mood disorders that
emphasize reduced inhibitory control by the PFC of
the amygdala and associated subcortical regions dur-
ing emotional processing (Haldane & Frangou, 2006).
Therefore we tested the hypotheses that during
the processing of sad facial stimuli : (a) the Met158 allele
will be associated with ventral PFC ineﬃciency evi-
denced by enhanced activation in these regions in
Met158 carriers ; and (b) this eﬀect would be ampliﬁed
in participants with aﬀective morbidity.
Method
Participants
Patients were identiﬁed by clinicians’ referrals and
were included if they: (a) were aged between 17 and
65 years ; (b) fulﬁlled DSM-IV-R criteria (APA, 1994)
for BD, type I ; (c) had at least one ﬁrst-degree relative
unaﬀected by BD; and (d) no family history (up to
second degree) of schizophrenia or schizophrenia
spectrum disorders. Their relatives were invited to
participate, with the patients’ consent, if aged between
17 and 65 years and without a personal history of
bipolar spectrum disorders.
Healthy volunteers were recruited through adver-
tisement in the local press and were enrolled if they
were : (a) aged between 17 and 65 years and (b) had no
personal or family history of any Axis-I or -II DSM-IV
disorder. Healthy volunteers were selected so that
they matched both patients and relatives in gender
and level of education. Level of education was rated
on a 5-point scale ranging from 1 (no educational
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qualiﬁcation) to 5 (postgraduate university level
qualiﬁcations).
Exclusion criteria for the entire sample (patients,
relatives and controls) included: (a) head trauma re-
sulting in loss of consciousness ; (b) personal history of
neurological or medical disorders ; (c) family history
of hereditary neurological disorders ; and (d) fulﬁlling
DSM-IV criteria for lifetime drug or alcohol depen-
dence and drug or alcohol abuse in the preceding
6 months.
All participants were enrolled in the VIBES
(Frangou, 2009 ; Kempton et al. 2009 ; Walterfang et al.
2009). The study was approved by the Joint South
London and Maudsley and the Institute of Psychiatry
NHS Research Ethics Committee and written in-
formed consent was obtained from all participants.
Clinical assessment
All participants were interviewed personally by
trained psychiatrists, who were initially blind to diag-
nostic but not family status (BD family member or
unrelated control), using the Structured Clinical Inter-
view for DSM-IV (SCID) for Axis I (patient and non-
patient version) (First et al. 2002a, b) and the SCID-II
Personality Questionnaire for Axis II diagnoses (First
et al. 1997). Inter-rater reliability was k >0.91 for all
instruments. Where applicable, further information
about age of onset, number and polarity of previous
episodes, number of hospital admissions and current
medication (type, dose and duration) was collected
from medical notes. Family history of psychiatric
disorders was assessed using the Family Interview for
Genetic Studies (Maxwell, 1992) supplemented by
medical notes as necessary. All participants were
rated using the Hamilton Depression Rating Scale
(HAMD; Hamilton, 1960), the Young Mania Rating
Scale (YMRS; Young et al. 1978) and the Brief Psy-
chiatric Rating Scale (BPRS; Overall & Gorham, 1962).
Prior to scanning, all participants with an Axis I
disorder were assessed weekly over a minimum
period of 1 month to ensure that at each evaluation
they (a) scored <7 in the HAMD and YMRS and
(b) there had been no change to their medication
status. For all participants an estimate of current full-
scale IQ was obtained on the day of scanning using
the Wechsler Adult Intelligence Scale – Revised
(Wechsler, 1981).
A total of 92 BD patients from an equal number
of families were screened by telephone interview for
eligibility by a trained psychiatrist. Families of 53 BD
patients were enrolled in the study; these yielded 47
BD patients and 75 ﬁrst-degree relatives. The sample
included in this analysis consisted of 40 BD type I
patients, 25 healthy relatives, 22 relatives with another
Axis I diagnosis (15 with MDD and seven with an
anxiety disorder) and 50 healthy controls. Details are
shown in Fig. 1.
DNA extraction and genotyping
DNA was obtained from buccal swabs using estab-
lished procedures (Freeman et al. 2003). The COMT
Met158Val (rs4680) genotype was determined by a
TaqMan genotyping assay (Assay ID C_25746809_50;
Applied Biosystems, USA) using the manufacturer’s
instructions. Endpoint analysis was performed on an
ABI7900 DNA analyser and genotypes called with the
SDS package (ABI, USA) with a probability >95%. To
improve genotyping reliability suﬃcient additional
samples of similar DNA quality and concentration
were used to ﬁll a complete plate for genotyping
(382 samples and two controls). Allele frequencies in
unrelated individuals did not violate the Hardy–
Weinberg principle (x2=0.40, df=1, p=0.51). In total,
38 individuals (11 BD patients, seven healthy relatives,
ﬁve relatives with an Axis I diagnosis and 15 controls)
were Val158 homozygotes, 65 (18 BD patients, 11 heal-
thy relatives, 15 relatives with an Axis I diagnosis and
21 controls) were Met158Val heterozygotes and 35
(11 BD patients, seven healthy relatives, three relatives
with an Axis I diagnosis and 14 controls) were Met158
homozygotes.
Neuroimaging
Sad facial aﬀect discrimination task
This comprised a 5-min event-related task. Ten diﬀer-
ent facial identities (six female, four male ; http://
www.paulekman.com) depicting either 150% inten-
sity of a sad expression or a neutral expression were
presented in a pseudo-random order interspersed
with a ﬁxation cross. The 150% level of sadness in-
tensity was chosen to minimize ambiguity and uncer-
tainty about the nature of the stimuli (Phillips et al.
1997 ; Calder et al. 1997). Each image was displayed for
2 s and the interstimulus interval followed a Poisson
distribution and was varied between 3 s and 9 s (mean
interval 5 s). In all, 60 images were displayed; the ﬁx-
ation cross, faces with neutral expression, and faces
expressing sadness were each presented 20 times.
Participants were instructed to indicate if the facial
aﬀect displayed was sad or neutral by pressing the
right or left button respectively on an MRI-compatible
response box. No response was required when sub-
jects viewed the ﬁxation cross. Response time and
accuracy data were collected.
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Image acquisition
Gradient echo planar MR images were acquired using
a 1.5 T GE Sigma MR system (General Electric, USA)
ﬁtted with 40 mT/m highspeed gradients. Foam pad-
ding and a forehead strap were used to limit head
motion, and a quadrature birdcage head coil was used
for radio frequency transmission and reception. In
each of the 16 non-contiguous planes parallel to the
inter-commissural [anterior commissure–posterior
commissure (AC–PC)] plane, T2*-weighted MR
images depicting blood-oxygenation level-dependent
(BOLD) contrast were acquired [repetition time (TR)=
2000 ms, echo time (TE)=40 ms, ﬂip angle=70x,
slice thickness=7 mm, slice skip=0.7 mm, matrix
size 64r64, voxel dimensions 3.75r3.75r7.7 mm].
During the facial aﬀect discrimination task 150
images were acquired. During the same session, a T1-
weighted three-dimensional inversion recovery pre-
pared spoiled gradient recalled acquisition sequence
was used to acquire structural images in 124 axial
planes [TR=18 ms, TE=5.1 ms, inversion time (TI)=
450 ms, ﬂip angle=20x, slice thickness=1.5 mm,
matrix size 256r192, ﬁeld of view 240r180 mm,
Screened for eligibility:
Families of 92 BD patients 
Excluded: 6 BD patients
for not meeting remission
criteria
Excluded:  
Not meeting inclusion criteria: 
40  
Refused to 
participate/unavailable: 
54 
Participated: 
75 relatives and 47 BD patients 
Enrolled:
53 BD patients and 169 of their first-degree relatives 
48 Relatives without any 
DSM-IV Axis I or II 
diagnoses 
27 relatives with Axis I 
DSM-IV diagnoses 
47 BD  
patients 
Included in current analysis: 
47 relatives and 40 BD patients 
Excluded: 28 relatives to achieve age 
matching/motion artefacts 
Excluded: 7 BD 
patients because of 
motion artefacts
Excluded: 
Families of 39 BD patients 
   Not meeting inclusion criteria: 
   Families of 15 BD patients 
   Refused to participate: 
   Families of 24 BD patients 
Fig. 1. Vulnerability to Bipolar Disorders Study (VIBES) sample : identiﬁcation and recruitment of bipolar disorder (BD)
patients and relatives.
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voxel dimensions 0.9375r0.9375r1.5 mm, number
of excitations=1] for subsequent Talairach mapping
(Talairach & Tourneaux, 1988).
Image analysis
Statistical analysis of the fMRI data was performed
using SPM5 (http://www.ﬁl.ion.ucl.ac.uk/spm)
analysis software, in a Matlab (version 7.01, The
Mathworks Inc., USA) environment. Images were
qualitatively assessed using the display function.
Images were realigned to the ﬁrst image in the dataset
to correct for movement and normalized into Montreal
Neurological Institute (MNI) space using the partici-
pant’s structural MRI image. The transformed dataset
for each subject was smoothed with an isotropic
Gaussian ﬁlter (full width half maximum=8 mm) to
compensate for normal variation in structural and
functional anatomy across subjects. Images demon-
strating acquisition or anatomical abnormalities were
excluded, as were individual scans showing trans-
lation >4 mm or rotation >4x. On this basis, six BD
patients were excluded.
First-level analysis
Vectors of onset representing the correctly identiﬁed
sad faces and correctly identiﬁed neutral faces were
convolved with the haemodynamic response function,
global signal changes were removed and a high-pass
ﬁlter (128 s) was applied to remove low-frequency
artefacts for each subject. In the design matrix we also
modelled the ﬁxation cross, incorrect responses, and
subject button response, although contrasts comparing
these conditions were not used in the second-level
analysis. An explicit mask was used to ensure that
only voxels within the brain were included in the
analysis. We entered six movement parameters as
nuisance covariates and contrast images of brain acti-
vations associated with correct recognition of sad faces
compared with neutral faces were produced for each
participant.
Second-level analysis
For the second-level analysis, a random-eﬀects model
was implemented. Weighted parameter estimates
were extracted from contrast images produced at the
ﬁrst level using MarsBaR (Brett et al. 2002) from a priori
ROIs. The selection of ROIs was based on known
anatomical and functional connectivity of the amyg-
dala and the ventral PFC (Ramnani & Owen, 2004;
Dolan, 2007) and on the eﬀect of the COMT genotype
in these regions during emotional processing tasks
(Mier et al. 2009). ROIs were deﬁned bilaterally in
the amygdala, the ventromedial PFC [Brodmann area
(BA) 11] and ventrolateral PFC (BA 47) using WFU
PickAtlas (Maldjian et al. 2003). To examine the eﬀect
of aﬀection status and genotype on activations in each
region, an analysis of covariance was performed in
SPSS version 15.0 (SPSS Inc., USA). Aﬀection status
(BD, relatives with MDD and anxiety disorders,
healthy relatives, and healthy controls) and COMT
genotype were entered as factors with age, BPRS
scores and reaction time as covariates. Signiﬁcant
main eﬀects or interactions were further examined
using post-hoc, Bonferroni-corrected, pairwise com-
parisons. Only ﬁndings below p<0.01 are reported.
Although we had data on HAMD and YMRS scores
from the entire sample, these scales are not validated
in non-clinical populations. Since all three scales were
highly correlated (r>0.733, p<0.0001) we chose the
BPRS as a covariate as it allows for meaningful com-
parisons between clinical and non-clinical groups.
We used t tests to compare mean weighted par-
ameter estimates from each of the ROIs between
unmedicated and medicated BD patients in order to
explore the possible contribution of medication to our
ﬁndings.
Results
Detailed information on sample characteristics and
behavioural performance is shown in Table 1. All par-
ticipants were of self-reported white British ancestry.
Behavioural data
Group diﬀerences were identiﬁed in reaction time
[F(3, 138)=3.39, p=0.02] ; BD patients had longer
mean reaction time compared with controls and
healthy relatives (both p<0.04). There was no eﬀect of
genotype [F(2, 138)=0.44, p=0.64] nor an interaction
between group and genotype [F(6, 138)=1.08, p=0.37]
in reaction time. There was no eﬀect of group
[F(3, 138)=2.76, p=0.06] or genotype [F(2, 138)=1.33,
p=0.26] in accuracy; their interaction was also not
signiﬁcant [F(6, 138)=2.03, p=0.07].
Functional imaging
There was no diﬀerence in brain activation between
medicated and unmedicated BD patients in any of the
ROIs examined (p>0.65) and therefore medication
status was not considered in further analyses.
There was a signiﬁcant eﬀect of genotype on
amygdala activation [left : F(2, 138)=5.76, p=0.04 ;
right : F(2, 138)=2.73, p=0.07], with Val158 homo-
zygotes having the highest percentage BOLD signal
change and Met158 homozygotes having the lowest
on both sides. There was no eﬀect of group (both
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p>0.13) or genotypergroup interaction (both p>
0.29). Similarly, none of the covariates was signiﬁcant
(all p>0.39).
There was a signiﬁcant eﬀect of genotype on
ventromedial PFC (BA 11) activation [left : F(2, 138)=
3.07, p=0.05 ; right : F(2, 138)=6.71, p=0.002], with
Met homozygotes having higher percentage BOLD
signal change on both sides compared with Val
carriers, but no eﬀect of group (both p>0.10) or geno-
typergroup interaction (both p>0.15). Likewise,
none of the covariates showed a signiﬁcant eﬀect
(all p>0.36).
In the ventrolateral PFC, a signiﬁcant eﬀect of group
[F(3, 138)=3.76, p=0.01] and a grouprgenotype
interaction [F(6, 138)=2.21, p=0.01] was observed on
the right (Fig. 2). There was no signiﬁcant eﬀect of
genotype (p>0.9) or of group (p>0.9), or of groupr
genotype interaction (p>0.37) on left BA 47. In
participants with an Axis I diagnosis (BD, MDD or
anxiety disorders) the Met158 allele was associated with
the greatest and the Val158 allele with the lowest acti-
vation (p=0.03). The eﬀect size of the diﬀerence com-
pared with controls was greater for relatives with
MDD and anxiety disorder (Cohen’s d=1.5) than for
BD patients (d=0.49) and healthy relatives (d=22).
It was not possible to compare the eﬀect of the COMT
genotype between relatives with MDD and those with
anxiety disorders because the number of subjects in
each group was too small.
Discussion
We found a pleiotropic eﬀect of COMT Val158Met
genotype on PFC and amygdala activation during
sad facial aﬀect processing. Speciﬁcally we found an
eﬀect of genotype but not clinical diagnosis or their
interaction in the amygdala and ventromedial PFC in
BA 11. The Val158 allele was associated with greater
amygdala activation while in the ventromedial PFC
signal change was greater for the Met158 allele. In the
right ventrolateral PFC the Met158 allele was not only
associated with increased signal change but also with
disease expression.
According to the model proposed by Bilder et al.
(2004), DA regulation within limbic regions depends
on the interplay between high-amplitude ‘phasic ’ DA
release in response to salient environmental stimuli
and low-level, ‘ tonic ’ DA concentration regulated
by PFC aﬀerents. DA catabolism in the amygdala is
mainly mediated by the DA transporter (Revay et al.
1996), as the COMT concentration in this region is very
low (Hong et al. 1998). Our results are in complete
Table 1. Demographic, clinical and behavioural data
Controls
(n=50)
BD patients
(n=40)
Healthy
relatives
(n=25)
Relatives with
Axis I diagnosis
(n=22)
Demographic data
Age, years 34.9 (13.2) 44.0 (11.9) 34.9 (14.3) 32.5 (11.4)
IQ 121.71 (19.51) 118.58 (17.93) 119.15 (17.74) 111.18 (14.06)
Gender, male : female ratio 26 :24 19 :21 15 :10 9 :14
Clinical data
Age of onset, years – 24.63 (8.07) – 21.81 (8.95)
BPRS 24.34 (0.65) 27.4 (4.00)** 24.12 (0.44) 25.43 (2.01)
HAMD 0.22 (0.58) 4.70 (5.38)** 0.08 (0.27) 1.26 (1.81)
YMRS 0.12 (0.43) 1.47 (2.98)** 0.00 (0.00) 0.43 (1.23)
GAF – 76.7 (14.5)a 89.3 (4.6) 85.5 (6.9)
Illness duration, years – 19.94 (10.5)b – 3.95 (5.2)
Number of aﬀective episodes – 11.0 (15.0)b – 2.0 (2.3)
Behavioural data
Accuracy 36.52 (3.4) 34.75 (4.4) 34.48 (4.4) 35.47 (3.4)
Reaction time, s 1.18 (0.20) 1.34 (0.26)* 1.15 (0.13) 1.21 (0.13)
BD, Bipolar disorder ; IQ, intelligence quotient ; BPRS, Brief Psychiatric Rating Scale ; HAMD, Hamilton Depression Rating
Scale ; YMRS, Young Mania Rating Scale ; GAF, Global Assessment of Functioning.
Values are given as mean (standard deviation).
Mean value was signiﬁcantly greater than those of all the other groups : * p<0.04, ** p<0.003 (no other group diﬀerences).
aMean value was signiﬁcantly lower than those of all the other groups (p<0.02).
bMean value was signiﬁcantly greater than that of the relatives with an Axis I diagnosis (p<0.006).
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agreement with this model since lower tonic DA con-
centration in the amygdala, associated with the high-
activity COMT Val158 allele, is predicted to enhance
the amplitude of phasic DA release (Rosenkranz &
Grace, 1999). Our results also conﬁrm the previously
reported (Mier et al. 2009) association between the
Met158 allele and a greater (i.e. more ineﬃcient) acti-
vation in the ventral PFC.
Ventromedial PFC activation has repeatedly been
found during externally triggered or internally gen-
erated sadness (George et al. 1995 ; Lane et al. 1997 ;
Reiman et al. 1997 ; Damasio et al. 2000) and during
imitation of sad faces (Lee et al. 2008). In healthy sub-
jects, medial PFC activation has been associated with
the appraisal of emotions (Lane et al. 1997 ; Teasdale
et al. 1999) and with self-referential evaluation (Kircher
et al. 2000 ; Kelley et al. 2002). In this context, the Met158
allele is likely to decrease cortical eﬃciency in the
processing and appraising of sad aﬀect relative to
the Val158 allele although our data suggest that this
association is not related to disease expression.
In the ventrolateral PFC (BA 47), the Met158 allele
was associated with greater activation in BD patients
and their relatives with MDD and anxiety disorders.
It is also noteworthy that the eﬀect size of the impact
of the COMT Val158Met genotype was greater in those
individuals with MDD and anxiety disorders than in
those with BD. Abnormal ventrolateral PFC engage-
ment has been reported in BD, MDD and anxiety dis-
orders across a number of paradigms involving
elements of inhibitory control (Blumberg et al. 2003 ;
Altshuler et al. 2005 ; McClure et al. 2007 ; Foland et al.
2008). It is generally accepted that the ventrolateral
PFC regulates stimulus-driven action by modulating
the inﬂuence of emotional stimuli on cognition with
respect to appropriate behaviour (Quirk & Beer, 2006).
Our results suggest that the Met158 allele reduces in-
hibitory capacity by decreasing cortical eﬃciency in
the ventrolateral PFC and that this eﬀect is associated
with disease expression.
Although medication eﬀects cannot be excluded
they are unlikely to have contributed to our ﬁndings.
Similarly, diﬀerences in brain activation cannot be
attributed to underlying structural volumetric group
diﬀerences as we have already shown in a previous
report from the VIBES sample (Kempton et al. 2009).
Although an eﬀect of the COMT genotype on brain
structure has been reported in some studies (Honea
et al. 2009), this is likely to be small (Dutt et al. 2009).
In summary, our study supports the notion that
the COMT Val158Met polymorphism is relevant to
mood disorders where increased limbic activation and
0.25
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0.15
0.10
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ValVal ValMet MetMet
0
1.0
0.8
0.6
0.4
0.2
0
–0.2
–0.4
–0.6
0.2
0.4
0.6
0.8
1.0
ValVal ValMet MetMet
ValVal ValMet MetMet
Controls Healthy relatives
BD patientsRelatives with Axis I diagnosis
Controls Healthy relatives
BD patientsRelatives with Axis I diagnosis
Controls Healthy relatives
BD patientsRelatives with Axis I diagnosis
Mean signal intensity in the vmFPC
(% whole brain volume signal change)
Mean signal intensity in the right vIFPC
(% whole brain volume signal change)
Mean signal intensity in the amygdala
(% whole brain volume signal change)
Fig. 2. Eﬀect of catechol-O-methyltransferase (COMT) Val158Met genotype on brain activation in bipolar disorder (BD)
patients and their relatives. Axial section at axial z=x11 showing the regions of interest examined : ventromedial prefrontal
cortex (vmPFC) (blue), ventrolateral prefrontal cortex (vlPFC) (turquoise) and the amygdala (green). Graphs show the
mean weighted estimates of neural responses in regions of interest deﬁned using WFU PickAtlas extracted using MarsBaR:
(i) bilateral vmPFC, (ii) right vlPFC and (iii) bilateral amygdala, by aﬀection status and COMT Val158Met genotype.
COMT and sad facial aﬀect in mood disorders 7
reduced PFC inhibitory control are considered key
pathophysiological features (Mayberg, 1997 ; Phillips,
2003). Our results are consistent with previous litera-
ture suggesting that the Met158 allele may confer in-
creased risk of aﬀective morbidity but also underscore
the pleiotropic eﬀect of the polymorphism in diﬀerent
brain regions during emotional processing. Addition-
ally, our ﬁndings highlight the importance for de-
veloping strategies to elucidate the gene interactions
that contribute to variation in penetrance, severity and
subtype of disorders of aﬀective dysregulation.
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